These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 25716136)

  • 1. Healthcare costs and resource utilization of asthma in Germany: a claims data analysis.
    Jacob C; Bechtel B; Engel S; Kardos P; Linder R; Braun S; Greiner W
    Eur J Health Econ; 2016 Mar; 17(2):195-201. PubMed ID: 25716136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-of-illness study of asthma in Korea: estimated from the Korea National Health insurance claims database].
    Park CS; Kang HY; Kwon I; Kang DR; Jung HY
    J Prev Med Public Health; 2006 Sep; 39(5):397-403. PubMed ID: 17076180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
    Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
    J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance.
    Stock SA; Stollenwerk B; Redaelli M; Civello D; Lauterbach KW
    J Womens Health (Larchmt); 2008 Apr; 17(3):343-54. PubMed ID: 18338965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone.
    Gerhardsson de Verdier M; Andersson M; Kern DM; Zhou S; Tunceli O
    Value Health; 2015 Sep; 18(6):759-66. PubMed ID: 26409602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis.
    Krüger K; von Hinüber U; Meier F; Tian H; Böhm K; Jugl SM; Borchert K; Meise D; König C; Braun S
    Rheumatol Int; 2018 Nov; 38(11):2121-2131. PubMed ID: 30094685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs.
    Sawicki GS; Vilk Y; Schatz M; Kleinman K; Abrams A; Madden J
    J Asthma; 2010 Jun; 47(5):574-80. PubMed ID: 20560831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Friedman HS; Yawn BP
    Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.
    Lage MJ; Gross GN; Brewster C; Spalitto A
    Adv Ther; 2009 Aug; 26(8):762-75. PubMed ID: 19669630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings.
    Black J; Reaven NL; Funk SE; McGaughey K; Ohayon M; Guilleminault C; Ruoff C; Mignot E
    Sleep Med; 2014 May; 15(5):522-9. PubMed ID: 24768358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.
    Luskin AT; Antonova EN; Broder MS; Chang E; Raimundo K; Solari PG
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1117-1124. PubMed ID: 29083971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of CHIP coverage on children with asthma in Alabama.
    Menachemi N; Blackburn J; Sen B; Morrisey MA; Becker DJ; Caldwell C; Kilgore ML
    Clin Pediatr (Phila); 2012 Mar; 51(3):247-53. PubMed ID: 21890839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Societal burden of cluster headache in the United States: a descriptive economic analysis.
    Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
    J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Out-of-pocket medication costs and use of medications and health care services among children with asthma.
    Karaca-Mandic P; Jena AB; Joyce GF; Goldman DP
    JAMA; 2012 Mar; 307(12):1284-91. PubMed ID: 22453569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic impact of children dispensed asthma medications without an asthma diagnosis.
    Stempel DA; Spahn JD; Stanford RH; Rosenzweig JR; McLaughlin TP
    J Pediatr; 2006 Jun; 148(6):819-23. PubMed ID: 16769395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic costs for adult asthmatics according to severity and control status in Korean tertiary hospitals.
    Kim SH; Kim TW; Kwon JW; Kang HR; Lee YW; Kim TB; Kim SH; Park HW; Park SW; Chang YS; Cho YS; Park JW; Cho YJ; Yoon HJ; Cho SH; Choi BW; Moon HB; Min KU
    J Asthma; 2012 Apr; 49(3):303-9. PubMed ID: 22185405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population.
    Colice G; Wu EQ; Birnbaum H; Daher M; Marynchenko MB; Varghese S
    J Occup Environ Med; 2006 Aug; 48(8):794-802. PubMed ID: 16902372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
    Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.